Announced
Completed
Synopsis
AbbVie, an American pharmaceutical company, completed the acquisition of Landos Biopharma, a clinical stage biopharmaceutical company, for $212m. "Many people living with IBD are not able to achieve or maintain remission and continue to experience debilitating symptoms. The addition of NX-13 complements our portfolio in immunology and strengthens our collective efforts to transform standard of care. I want to commend the Landos team for their efforts in advancing our shared mission of developing medicines for those who need it most," Kori Wallace, AbbVie Vice President, Global Head of Immunology Clinical Development.
Principals
Show Details & Financials
Sort
Search a database of more than 250,000 verified dealmakers
Receive automated updates on global transactions
Follow the activity, relationships and transactions of top dealmakers
© COPYRIGHT 2024 MERGERLINKS LIMITED.
ALL RIGHTS RESERVED.
15 BONHILL STREET, LONDON, EC2A 4DN, UNITED KINGDOM.